Table 3.
Bone turnover markers were evaluated in five of the articles. Variable results were obtained for Serum Procollagen type I N-Terminal propeptide (P1NP) and for Serum collagen type I crosslinked C-telopeptide (CTX). P1NP increased in transwomen and transmen. CTX showed similar values before and after treatment.
| Author and Year of Publication | Sample | Bone Turnover Markers | |||||
|---|---|---|---|---|---|---|---|
| M to F | F to M | Serum Procollagen Type I N-Terminal Propeptide (P1NP) Formation (ng/mL) | Serum Collagen type I Crosslinked C-Telopeptide (CTX) Resorption (ng/mL) | ||||
| Before or Controls | After or Tests | Before or Controls | After or Tests | ||||
| Schlatterer K et al. 1998 [37] | 10 | 10 | M to F | M to F | Not evaluated | Not evaluated | Not evaluated |
| F to M | F to M | Not evaluated | Not evaluated | Not evaluated | |||
| Sosa M et al. 2003 [38] | 53 | - | M to F | Not evaluated | Not evaluated | Not evaluated | Not evaluated |
| Ruetsche AG et al. 2005 [39] | 24 | 15 | M to F | Not evaluated | Not evaluated | Not evaluated | Not evaluated |
| F to M | Not evaluated | Not evaluated | Not evaluated | Not evaluated | |||
| Lapauw B et al. 2008 [40] | 23 | - | M to F | 32 [24,25,26,27,28,29,30,31,32,33,34,35,36,37,38,39,40,41,42,43,44,45] (46 controls) | 49 [36,37,38,39,40,41,42,43,44,45,46,47,48,49,50,51,52,53,54,55,56,57,58,59,60,61,62] (23 patients) | 0.36 ± 0.16 (46 controls) | 0.24 ± 0.14 (23 patients) |
| T’Sjoen G et al. 2009 [41] | 50 | - | M to F | Lumbar spine 36.6 ± 22.6 | Lumbar spine 45.2 ± 24.4 | 0.31 ± 0.20 | 0.32 ± 0.23 |
| Van Caenegem, et al. 2012 [42] | - | 66 | F to M Before Surgery | 40 ± 12 | 50 ± 24 | 0.20 ± 0.10 | 0.36 ± 0.15 |
| Wierckx K et al. 2012 [43] | 50 | 50 | M to F | 102 ng/mL | 106–125 (ng/mL) (2 patients, all the others were within normal ranges) | <0.58 (ng/dL) | 0.62–1.24 (ng/dL) (4 patients, all the others were within normal ranges) |
| F to M | Normal range | Normal range | Normal range | Normal range | |||
| Wiepjes C et al. 2018 [44] | 711 | 543 | M to F | Not evaluated | Not evaluated | Not evaluated | Not evaluated |
| F to M | Not evaluated | Not evaluated | Not evaluated | Not evaluated | |||
| Broulik PD et al. 2018 [45] | - | 35 | F to M | Not evaluated | Not evaluated | Control Female 400 ± 124 | 302 ± 190 |
| Control Male 390 ± 140 | |||||||
PINP in M to F: Bone formation marker PINP increased from 32–49 ng/mL [40], and from 102–125 ng/mL [43]. PINP in F to M: Bone formation marker PINP increased from 40 ± 12–50 ± 24 ng/mL [42]. CTX in M to F: Bone resorption marker, decreased in one study from 0.36 ± 0.16–0.24 ± 0.14 ng/mL [40], and increased in another study from <0.58 ng/dL to 0.62–1.24 ng/dL [43]. CTX in F to M: Bone resorption marker CTX increased from 0.20 ± 0.10–0.36 ± 0.15 ng/mL [42], and was maintained within the normal range [41,43], and decreased from 400 ± 124–302 ± 190 ng/mL [45].